From: Board of Pharmacy <pharmacy.subscriberlist@DCA.CA.GOV>
Sent: Wednesday, April 19, 2017 5:19 PM
To: PHARM-GENERAL@DCALISTS.CA.GOV
Cc: Pharmacy_Subscriberlist@DCA
Subject: Market Withdrawal - Gilead Sciences Inc.

Gilead Sciences Inc. is withdrawing VITEKTA (elvitegravir 85 mg and 150 mg) tablets from sale as of February 2017.

This decision is based on low utilization of the product (less than 50 US patients taking VITEKTA) and is not a result of any ongoing or new quality or safety issues with VITEKTA. Gilead believes there is no unmet medical need for VITEKTA because of the availability of other antiretroviral agents with indications broad enough to be inclusive of the VITEKTA indication. Given the alternatives available, this withdrawal will not deprive patients of viable treatment options. Importantly, the withdrawal of VITEKTA as a standalone product will not impact the availability of fixed-dosed combinations that contain elvitegravir.

Please immediately check your inventory, quarantine, discontinue distribution of the affected product, and contact your wholesaler for directions.

Product Description	**NDC**	**Lot#**	**Expiration Date**
VITEKTA (elvitegravir) 85 mg tablets	61958-1301-1	MFSHA	Feb 2017
VITEKTA (elvitegravir) 150 mg tablets	61958-1302-1	MFSDA	Feb 2017
		THCK	May 2019